NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

192.62B

Vuru Grade

69.64/100

Current Price

$80.89
+0.01 (+0.01%)

Growth Price

$56.04
Overvalued by 30.72%

Stability Price

$14.58
Overvalued by 81.98%

Company Metrics

  • P/E 28.88
  • P/S 3.87
  • P/B 2.66
  • EPS 2.80
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.34 %
  • Avg. Vol. 1.31M
  • Shares 2.38B
  • Market Cap. 192.62B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Activity Reported By SEC: Ls Investment Advisors LLC Lowered Its Novartis Ag ...
Chester News - Sep 27, 2016
Ls Investment Advisors Llc decreased its stake in Novartis Ag Spon Adr (NVS) by 97.91% based on its latest 2016Q2 regulatory filing with the SEC.
Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope
TCC - Sep 19, 2016
Novartis AG (ADR) (NYSE:NVS) investigational molecule for the treatment and management of multiple sclerosis has shown remarkable reduction in the disease progression up to 21%.
Novartis AG (ADR) (NYSE:NVS) Heffx Trading Outlook
Live Trading News - Sep 26, 2016
During the past 10 bars, there have been 7 white candles and 3 black candles for a net of 4 white candles. During the past 50 bars, there have been 29 white candles and 21 black candles for a net of 8 white candles.
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
TCC - Aug 8, 2016
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Here's What's Important With The Novartis AG (ADR) (NVS) MS Data
Insider Monkey (blog) - Aug 29, 2016
Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers a solution for patients with secondary progressive MS (SPMS), a severe form ...
Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words - Market Exclusive
Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration - TCC
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Market Exclusive - Mar 25, 2016
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Chardan Capital Initiates Coverage on Novartis AG (ADR) to Buy
Trade Calls - Sep 27, 2016
Chardan Capital Initiates Coverage on Novartis AG (ADR)(NYSE:NVS). The shares have been rated Buy. The rating by Chardan Capital was issued on Sep 20, 2016.
The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been ...
TCC - Aug 31, 2016
In a latest development, the Food and Drug Administration (FDA) has announced the approval of Novartis AG's (NYSE:NVS) Erelzi, which is a biosimilar version of Amgen's blockbuster drug Enbrel.
Novartis AG (ADR) Enbrel Biosimilar Approved: What's Next for Amgen? - Smаrt Stоck Nеws
Amgen, Inc: How Damaging Will Be Novartis' Enbrel Copy - Bidness ETC
Amgen, Inc. (AMGN) and Novartis AG (ADR) (NVS) Erenumab: New Hope for Migraine ...
TCC - Sep 16, 2016
Amgen, Inc. (NASDAQ:AMGN) has announced that erenumab clinical results for the management and treatment of chronic migraine headaches have met the primary endpoints.
Novartis AG (ADR) 17% Potential Upside Now Implied by Chardan Capital Markets
DirectorsTalk Interviews - Sep 21, 2016
Novartis AG (ADR) with TICKER NYSE:NVS has had its stock rating noted as 'Initiated' with the recommendation being set at 'BUY' yesterday by analysts at Chardan Capital Markets.